TheraCryf (LSE:TCF) ROCE %: -50.92% (As of Sep. 2025)


What is TheraCryf ROCE %?

TheraCryf LSE:TCF ROCE % is -50.92% as of Sep. 2025. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TheraCryf's annualized ROCE % for the quarter that ended in Sep. 2025 was -50.92%.

TheraCryf  (LSE:TCF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TheraCryf ROCE % Related Terms

TheraCryf ROCE % Historical Data

* Premium members only.

The historical data trend for TheraCryf's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TheraCryf ROCE % Chart

TheraCryf Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -40.01 -30.34 -69.60 -92.70 -50.91

TheraCryf Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.92 -133.93 -99.84 -40.06 -50.92

TheraCryf ROCE % Calculation

TheraCryf's annualized ROCE % for the fiscal year that ended in Mar. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=-2.115/( ( (3.062 - 0.722) + (7.63 - 1.662) )/ 2 )
=-2.115/( (2.34+5.968)/ 2 )
=-2.115/4.154
=-50.91 %

TheraCryf's ROCE % of for the quarter that ended in Sep. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2025 )  (Q: Mar. 2025 )(Q: Sep. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2025 )  (Q: Mar. 2025 )(Q: Sep. 2025 )
=-2.742/( ( (7.63 - 1.662) + (6.618 - 1.816) )/ 2 )
=-2.742/( ( 5.968 + 4.802 )/ 2 )
=-2.742/5.385
=-50.92 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -50.92% mean?
TheraCryf (LSE:TCF) has a ROCE % of -50.92% as of Sep. 2025.
Is TheraCryf's ROCE % too high?
TheraCryf's current ROCE % is -50.92%.
How does TheraCryf's ROCE % compare to VRTX and REGN?
TheraCryf's ROCE % of -50.92% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. TheraCryf's current ROCE % is -50.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TheraCryf stock overvalued right now?
TheraCryf (LSE:TCF) has a current ROCE % of -50.92%. The current ROCE % is -50.92%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For TheraCryf (LSE:TCF), the current ROCE % is -50.92% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TheraCryf Business Description

Address Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG
TheraCryf PLC is a clinical stage therapeutics company developing therapeutic candidates for behavioural brain disorders such as opioid and alcohol addiction, and acute/chronic fatigue. It focuses on data generation to support potential partnerships for its programs with mid-sized and large pharmaceutical companies. The company's pipeline includes Ox-1 - Substance Use Disorders (SUDs) / Anxiety, DAT - Fatigue and Narcolepsy, SFX-01, and SFX-01- Neurodevelopmental Disorders.